- Research works
- 76 ▲ 48% vs 2013–17
- Citations
- 868 11.5 per fractional work
- Top-10% rate
- 16.2% record average 16.5%
- Open access
- 53% world 28%
Not ranked overall: Novo Nordisk (India) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Novo Nordisk (India) specialise in?
Where its research is concentrated relative to its size: Medicine takes 3.7× the share of its output that it takes of world research.
- MedicineField · 20.8 works3.7×
- Health SciencesDomain · 22.0 works3.2×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 16.6×. Every wedge is a field page.
- Veterinary 16.6×
- Medicine 3.7×
- Economics, Econometrics and Finance 1.7×
- Pharmacology, Toxicology and Pharmaceutics 1.6×
- Nursing 1.5×
- Neuroscience 1.2×
- Mathematics 1.0×
- Biochemistry, Genetics and Molecular Biology 0.9×
- Immunology and Microbiology 0.8×
- Materials Science 0.7×
- Environmental Science 0.4×
- Health Professions 0.4×
- Agricultural and Biological Sciences 0.4×
- Computer Science 0.3×
- Engineering 0.2×
- Business, Management and Accounting 0.2×
- Psychology 0.1×
Which keywords describe research at Novo Nordisk (India)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Glycemic Control, Insulin Therapy, Diabetes, Cardiovascular Disease, Type 2 Diabetes, Metabolic Syndrome, Clinical Guidelines and Heart Failure.
- Intensive Care Unit
- NAFLD
- Inflammation
- Critical Care
- Hyperglycemia
- Weight Loss
- Cholesterol
- Cardiovascular Risk
- Lifestyle Intervention
- Hypoglycemia
- Insulin Resistance
- Type 1 Diabetes
- Cardiovascular Outcomes
- Heart Failure
- Clinical Guidelines
- Cardiovascular Disease
- Insulin Therapy
- Glycemic Control
- Diabetes
- Type 2 Diabetes
- Metabolic Syndrome
- Obesity
- Glucose Control
- Complications
- Continuous Glucose Monitoring
- Epidemiology
- Atherosclerosis
- Glucose Metabolism
- Global Prevalence
- Diabetes Mellitus
- Clinical Trials
- Hepatic Steatosis
- Mortality
- NASH
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 34 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 34 words, with their numbers
- Glycemic Control7▲ 151×4 topics
- Insulin Therapy7▲ 186×3 topics
- Diabetes6▲ 39×7 topics
- Cardiovascular Disease4▲ 14×8 topics
- Type 2 Diabetes4▲ 64×3 topics
- Clinical Guidelines4▲ 42×4 topics
- Metabolic Syndrome4▲ 15×8 topics
- Heart Failure3▲ 26×3 topics
- Obesity3▲ 15×10 topics
- Cardiovascular Outcomes3▲ 199×1 topic
- Glucose Control3▲ 199×1 topic
- Type 1 Diabetes3▲ 109×2 topics
- Complications3▲ 18×2 topics
- Insulin Resistance3▲ 20×4 topics
- Continuous Glucose Monitoring2▲ 183×1 topic
- Hypoglycemia2▲ 183×1 topic
- Epidemiology2▲ 1.94×16 topics
- Lifestyle Intervention2▲ 90×2 topics
- Atherosclerosis2▲ 23×3 topics
- Cardiovascular Risk2▲ 16×5 topics
- Glucose Metabolism2▲ 53×2 topics
- Cholesterol1▲ 34×1 topic
- Global Prevalence1▲ 54×1 topic
- Weight Loss1▲ 29×4 topics
- Diabetes Mellitus1▲ 22×3 topics
- Hyperglycemia1▲ 36×2 topics
- Clinical Trials1▲ 5.8×6 topics
- Critical Care1▲ 17×3 topics
- Hepatic Steatosis1▲ 25×2 topics
- Inflammation1▲ 1.83×10 topics
- Mortality1▲ 6.2×2 topics
- NAFLD1▲ 30×1 topic
- NASH1▲ 30×1 topic
- Intensive Care Unit1▲ 29×2 topics
Which research topics does Novo Nordisk (India) publish most on?
By volume in 2022–2025: Diabetes Treatment and Management, Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins and Liver Disease Diagnosis and Treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 3 works
- 2 Diabetes Management and Research Endocrinology, Diabetes and Metabolism 2 works
- 3 Diabetes, Cardiovascular Risks, and Lipoproteins Endocrinology, Diabetes and Metabolism 1 works
- 4 Liver Disease Diagnosis and Treatment Epidemiology 1 works
- 5 Hyperglycemia and glycemic control in critically ill and hospitalized patients Endocrinology, Diabetes and Metabolism 1 works
- 6 Bariatric Surgery and Outcomes Surgery 1 works
- 7 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 8 Metabolism, Diabetes, and Cancer Molecular Biology 1 works
- 9 Hemophilia Treatment and Research Hematology 0 works
- 10 Growth Hormone and Insulin-like Growth Factors Endocrinology, Diabetes and Metabolism 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Novo Nordisk (India)'s research output changed?
Output in 2018–2022 was 48% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Bengaluru
- Indian Institute of Science Bangalore
- Christ University
- Jain University
- National Institute of Mental Health and Neurosciences
- Bangalore University
- Indian Space Research Organisation
- PES University
- M S Ramaiah University of Applied Sciences
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.